HDL-C is associated with mortality from all causes,cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies
Restricted accessResearch articleFirst published online July, 2020
HDL-C is associated with mortality from all causes,cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies
The association between high-density lipoprotein cholesterol (HDL-C) levels and mortality remains controversial. We aimed to investigate the potential dose–response associations between HDL-C levels and mortality from all causes, cardiovascular disease and cancer in the general population.
Methods
PubMed and Embase were searched through April 2019. Prospective cohort studies reporting risk estimates of HDL-C levels and mortality were included. Linear and non-linear dose–response analyses were conducted. A random-effects model was employed to calculate pooled hazard ratio.
Results
Thirty-seven studies, involving 3,524,505 participants and more than 612,027 deaths, were included. HDL-C level was found to be associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose–response pattern, with the lowest risk observed at HDL-C levels of 54–58 mg/dL, 68–71 mg/dL and 64–68 mg/dL, respectively. Compared with HDL-C level of 56 mg/dL, the pooled hazard ratios for all-cause mortality were 1.03 (95% confidence interval (CI) 1.01, 1.05) and 1.10 (95% CI 1.09, 1.12) for each 10-mg/dL increase and decrease in HDL-C levels, respectively; furthermore, compared with the reference category, the pooled hazard ratios for all-cause mortality were 1.21 (95% CI 1.09, 1.36) and 1.36 (95% CI 1.21, 1.53) for the highest and the lowest categories of HDL-C levels, respectively. Similar results were obtained for cardiovascular and cancer mortality.
Conclusions
In the general population, HDL-C level is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose–response manner; both extremely high and low HDL-C levels are associated with an increased risk of mortality.
GordonDJProbstfieldJLGarrisonRJ, et al.
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation1989;
79: 8–15.
2.
CastelliWPGarrisonRJWilsonPW, et al.
Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA1986;
256: 2835–2838.
3.
Di AngelantonioESarwarNPerryP, et al.
Major lipids, apolipoproteins, and risk of vascular disease.JAMA2009;
302: 1993–2000.
4.
WilsonPWAbbottRDCastelliWP.High density lipoprotein cholesterol and mortality. The Framingham Heart Study.Arteriosclerosis1988;
8: 737–741.
5.
PekkanenJLinnSHeissG, et al.
Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med1990;
322: 1700–1707.
6.
LandrayMJHaynesRHopewellJC, et al.
Effects of extended-release niacin with laropiprant in high-risk patients.N Engl J Med2014;
371: 203–212.
7.
LincoffAMNichollsSJRiesmeyerJS, et al.
Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med2017;
376: 1933–1942.
8.
BodenWEProbstfieldJLAndersonT, et al.
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med2011;
365: 2255–2267.
9.
SchwartzGGOlssonAGAbtM, et al.
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med2012;
367: 2089–2099.
10.
BarterPJCaulfieldMErikssonM, et al.
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med2007;
357: 2109–2122.
11.
BowmanLHopewellJCChenF, et al.
Effects of anacetrapib in patients with atherosclerotic vascular disease.N Engl J Med2017;
377: 1217–1227.
12.
AngeloniEPaneniFLandmesserU, et al.
Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J2013;
34: 3557–3562.
13.
SilbernagelGSchottkerBAppelbaumS, et al.
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J2013;
34: 3563–3571.
14.
RidkerPMGenestJBoekholdtSM, et al.
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial. Lancet2010;
376: 333–339.
15.
ZanoniPKhetarpalSALarachDB, et al.
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science2016;
351: 1166–1171.
16.
LiZHLvYBZhongWF, et al.
High-density lipoprotein cholesterol and all-cause and cause-specific mortality among the elderly. J Clin Endocrinol Metab2019104: 3370–3378.
17.
OhIHHurJKRyooJH, et al.
Very high high-density lipoprotein cholesterol is associated with increased all-cause mortality in South Koreans. Atherosclerosis2019;
283: 43–51.
18.
HamerMO’DonovanGStamatakisE.High-density lipoprotein cholesterol and mortality: Too much of a good thing?Arterioscler Thromb Vasc Biol2018;
38: 669–672.
19.
MadsenCMVarboANordestgaardBG.Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: Two prospective cohort studies. Eur Heart J2017;
38: 2478–2486.
20.
BoweBXieYXianH, et al.
High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. Veterans. Clin J Am Soc Nephrol2016;
11: 1784–1793.
21.
HarariGGreenMSMagidA, et al.
Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up. Am J Cardiol2017;
119: 1193–1198.
22.
HirataAOkamuraTSugiyamaD, et al.
The relationship between very high levels of serum high-density lipoprotein cholesterol and cause-specific mortality in a 20-year follow-up study of Japanese general population. J Atheroscler Thromb2016;
23: 800–809.
23.
SungKCRyuSWildSH, et al.
An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart2015;
101: 553–558.
24.
SkrettebergPTGrundvoldIKjeldsenSE, et al.
HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness? A 28-year follow-up of apparently healthy men. Atherosclerosis2012;
220: 250–256.
StoneNJRobinsonJGLichtensteinAH, et al.
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2014;
63: 2889–2934.
27.
MoherDLiberatiATetzlaffJ, et al.
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ2009;
339: b2535.
28.
WilkinsJTNingHStoneNJ, et al.
Coronary heart disease risks associated with high levels of HDL cholesterol. J Am Heart Assoc2014;
3: e000519.
29.
StensvoldIUrdalPThurmerH, et al.
High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J1992;
13: 1155–1163.
30.
JacobsDRJrMebaneILBangdiwalaSI, et al.
High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol1990;
131: 32–47.
31.
CowanLDO’ConnellDLCriquiMH, et al.
Cancer mortality and lipid and lipoprotein levels. Lipid Research Clinics program mortality follow-up study. Am J Epidemiol1990;
131: 468–482.
32.
MazidiMMikhailidisDPBanachM.Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. Int J Cardiol2019;
276: 242–247.
33.
AkerblomJLCostaRLuchsingerJA, et al.
Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. Age Ageing2008;
37: 207–213.
34.
CortiMCGuralnikJMSaliveME, et al.
HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA1995;
274: 539–544.
KoDTAlterDAGuoH, et al.
High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: The CANHEART study. J Am Coll Cardiol2016;
68: 2073–2083.
37.
CooneyMTDudinaADe BacquerD, et al.
HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis2009;
206: 611–616.
38.
CuiYBlumenthalRSFlawsJA, et al.
Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med2001;
161: 1413–1419.
39.
OnatACanGKeskinM, et al.
Tenth categories of total and HDL cholesterol fail to independently predict death risk in middle-aged Turkish adults. Turk Kardiyol Dern Ars2017;
45: 590–598.
40.
LiYLiYMengL, et al.
Association between serum C-peptide as a risk factor for cardiovascular disease and high-density lipoprotein cholesterol levels in nondiabetic individuals. PLoS One2015;
10: e112281.
41.
HoutermanSVerschurenWMGiampaoliS, et al.
Total but not high-density lipoprotein cholesterol is consistently associated with coronary heart disease mortality in elderly men in Finland, Italy, and The Netherlands. Epidemiology2000;
11: 327–332.
42.
GhasemzadehZAbdiHAsgariS, et al.
Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population. Nutr Metab2016;
13: 43.
43.
DesquilbetLMariottiF.Dose–response analyses using restricted cubic spline functions in public health research. Stat Med2010;
29: 1037–1057.
44.
HamlingJLeePWeitkunatR, et al.
Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med2008;
27: 954–970.
45.
PensonPLongDLHowardG, et al.
Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical And Racial Differences in Stroke (REGARDS) study. Cardiovasc Res2019;
115: 204–212.
46.
Rahilly-TierneyCSessoHDMichael GazianoJ, et al.
High-density lipoprotein and mortality before age 90 in male physicians. Circ Cardiovasc Qual Outcomes2012;
5: 381–386.
47.
UpmeierELavoniusSLehtonenA, et al.
Serum lipids and their association with mortality in the elderly: A prospective cohort study. Aging Clin Exp Res2009;
21: 424–430.
48.
RaihaIMarniemiJPuukkaP, et al.
Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler Thromb Vasc Biol1997;
17: 1224–1232.
49.
ChandlerPDSongYLinJ, et al.
Lipid biomarkers and long-term risk of cancer in the Women’s Health Study. Am J Clin Nutr2016;
103: 1397–1407.
50.
OrsiniNBelloccoRGreenlandS.Generalized least squares for trend estimation of summarized dose–response data. Stata J2006;
6: 40–57.
51.
BeggCBMazumdarM.Operating characteristics of a rank correlation test for publication bias. Biometrics1994;
50: 1088–1101.
52.
EggerMDavey SmithGSchneiderM, et al.
Bias in meta-analysis detected by a simple, graphical test. BMJ1997;
315: 629–634.
53.
Weverling-RijnsburgerAWJonkersIJvan ExelE, et al.
High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med2003;
163: 1549–1554.
54.
HirataASugiyamaDWatanabeM, et al.
Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol2018;
12: 674–684 e675.
55.
Rahilly-TierneyCRSpiroA3rdVokonasP, et al.
Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study). Am J Cardiol2011;
107: 1173–1177.
56.
PaunioMHeinonenOPVirtamoJ, et al.
HDL cholesterol and mortality in Finnish men with special reference to alcohol intake.Circulation1994;
90: 2909–2918.
57.
Lazo-PorrasMBernabe-OrtizAMalagaG, et al.
Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study. Atherosclerosis2016;
246: 36–43.
58.
KatzkeVASookthaiDJohnsonT, et al.
Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort. BMC Med2017;
15: 218.
59.
PaunioMVirtamoJGrefCG, et al.
Serum high density lipoprotein cholesterol, alcohol, and coronary mortality in male smokers. BMJ1996;
312: 1200–1203.
60.
OkamuraTHayakawaTKadowakiT, et al.
The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis2006;
184: 143–150.
61.
TothPPBarterPJRosensonRS, et al.
High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol2013;
7: 484–525.
62.
NnoahamKEWebsterPKumbangJ, et al.
Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of case-control studies. Fertil Steril2012;
98: 702–712 e706.
63.
O’KeefeJHBybeeKALavieCJ.Alcohol and cardiovascular health: The razor-sharp double-edged sword. J Am Coll Cardiol2007;
50: 1009–1014.
64.
Agerholm-LarsenBNordestgaardBGSteffensenR J, et al.
Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation2000;
101: 1907–1912.
65.
AndersenRVWittrupHHTybjaerg-HansenA, et al.
Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: The Copenhagen City Heart Study. J Am Coll Cardiol2003;
41: 1972–1982.
66.
Frikke-SchmidtRNordestgaardBGJensenGB, et al.
Genetic variation in ABCA1 predicts ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol2008;
28: 180–186.
67.
BarterPJRyeKA.HDL cholesterol concentration or HDL function: Which matters?Eur Heart J2017;
38: 2487–2489.
68.
HuangCYLinFYShihCM, et al.
Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating rho-associated kinase pathways. Arterioscler Thromb Vasc Biol2012;
32: 2405–2417.
69.
PiepoliMFHoesAWAgewallS, et al.
2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of The European Society Of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association For Cardiovascular Prevention & Rehabilitation (EACPR).Eur Heart J2016;
37: 2315–2381.
70.
KircherTNelsonJBurdoH.The autopsy as a measure of accuracy of the death certificate. N Engl J Med1985;
313: 1263–1269.
71.
PerovaNVOganovRGWilliamsDH, et al.
Association of high-density-lipoprotein cholesterol with mortality and other risk factors for major chronic noncommunicable diseases in samples of US and Russian men. Ann Epidemiol1995;
5: 179–185
72.
GordonDJProbstfieldJLGarrisonRJ, et al.
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation1989;
79: 8–15
73.
WilsonPWAbbottRDCastelliWP.High density lipoprotein cholesterol and mortality. The Framingham Heart Study.Arteriosclerosis1988;
8: 737–741
74.
YaariSGoldbourtEven-ZoharS, et al.
Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10000 men. Lancet1981;
1: 1011–1015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
